In this study, PLL (Mw = 3 kDa) was conjugated to vasoactive intestinal peptide (VIP) in a 1:1 molar ratio to enhance the delivery of 131I-ASO to VIP-receptor-positive tumour cells. This evidence concerns the gene VIP and neoplasm.